NBY vs PCYO vs MSEX vs AYTU

For growth investors, Aytu BioPharma, Inc.

(AYTU) is the stronger pick with 1. 8% revenue growth year-over-year, versus -9. 3% for Pure Cycle Corporation (PCYO). Pure Cycle Corporation (PCYO) offers the better valuation at 21. 6x trailing P/E, making it the more compelling value choice. Analysts rate Pure Cycle Corporation (PCYO) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Pure Cycle Corporation (PCYO) is the cheapest at 21.

6x versus Middlesex Water Company at 21. 8x.

Over the past 5 years, Pure Cycle Corporation (PCYO) delivered a total return of -19.

8%, compared to -99. 9% for NovaBay Pharmaceuticals, Inc. (NBY). Over 10 years, the gap is even starker: PCYO returned +159. 6% versus AYTU's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Middlesex Water Company (MSEX) is the lower-risk stock at -0.

12β versus NovaBay Pharmaceuticals, Inc. 's 2. 43β — meaning NBY is approximately -2056% more volatile than MSEX relative to the S&P 500. On balance sheet safety, Pure Cycle Corporation (PCYO) carries a lower debt/equity ratio of 5% versus 121% for Aytu BioPharma, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Aytu BioPharma, Inc.

(AYTU) is pulling ahead at 1. 8% versus -9. 3% for Pure Cycle Corporation (PCYO). On earnings-per-share growth, the picture is similar: NovaBay Pharmaceuticals, Inc. grew EPS 98. 2% year-over-year, compared to -4. 5% for Middlesex Water Company. Over a 3-year CAGR, MSEX leads at 6. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pure Cycle Corporation (PCYO) is the more profitable company, earning 50.

3% net margin versus -73. 8% for NovaBay Pharmaceuticals, Inc. — meaning it keeps 50. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PCYO leads at 29. 4% versus -59. 7% for NBY. At the gross margin level — before operating expenses — AYTU leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, MSEX (2.

7% yield) pays a dividend. NBY, PCYO, AYTU do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Middlesex Water Company (MSEX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

12), 2. 7% yield). NovaBay Pharmaceuticals, Inc. (NBY) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MSEX: +62. 9%, NBY: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NBY (Healthcare) and PCYO (Utilities) and MSEX (Utilities) and AYTU (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

MSEX pays a dividend while NBY, PCYO, AYTU do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.